Attenuating effect of Lactobacillus brevis G101 on the MSG symptom complex in a double-blind, placebo-controlled study.
- Author:
Dong Hyun KIM
1
;
Yeji CHOI
;
Sun Sung PARK
;
Se Young KIM
;
Myung Joo HAN
Author Information
- Publication Type:Randomized Controlled Trial ; Brief Communication
- Keywords: Monosodium glutamate; side effect; Lactobacillus brevis G10; blind study
- MeSH: Absorption; Administration, Oral; Animals; Capsules; Surveys and Questionnaires; Humans; Intestines; Lactobacillus brevis*; Lactobacillus*; Mice; Sodium Glutamate*; Soybeans
- From:Nutrition Research and Practice 2015;9(6):673-676
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/OBJECTIVES: Lactobacillus brevis G101 suppresses the absorption of monosodium glutamate (MSG) from the intestine into the blood in mice. Therefore, the attenuating effect of orally administered G101 on monosodium glutamate (MSG) symptom complex was investigated in humans. MATERIALS/METHODS: Capsules (300 mg) containing Lactobacillus brevis G101 (1x1010 CFU/individual) or maltodextrin (placebo) was orally administered in 30 respondents with self-recognized monosodium glutamate (MSG) symptom complex for 5 days and the rice with black soybean sauce containing 6 g MSG (RBSM) was ingested 30 min after the final administration. Thereafter, the MSG symptom complex (rated on a 5-point scale: 1, none; 5, strong) was investigated in a double blind placebo controlled study. The intensity of the MSG symptom complex was significantly reduced in respondents of the G101 intake group (2.87 +/- 0.73) compared to that in those treated with the placebo (3.63 +/- 1.03) (P = 0.0016). Respondents in the placebo group exhibited more of the various major conditions of the MSG symptom complex than in the G101 intake group. Although there was no significant difference in the appearance time of the MSG symptom complex between subjects orally administered G101 and those administered the placebo, its disappearance in < 3 h was observed in 69.9% of subjects in the G101 treatment group and in 38.0% of subjects in the placebo group (P = 0.0841). CONCLUSIONS: Oral administration of Lactobacillus brevis G101 may be able to reduce the intensity of the MSG symptom complex.
